QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Advaxis, Inc. (ADXS) Leverages The Immune System 0 comments
    Mar 19, 2013 3:03 PM | about stocks: ADXS

    The human body's primary defense against diseased cells is a strong immune system, a complex system of cellular level processes that has evolved to both identify and take action against foreign or diseased cells, including cells developing into cancer cells. It is believed that the human body is constantly generating at least some cancer cells, but that the body's immune system is generally able to handle them. However, a defective immune system, a system compromised by a genetic problem, or environmental factors, or weakened by changes related to the aging process, leaves the body vulnerable to internal or external attack.

    For example, it appears that an aging immune system is simply less effective in dealing with cancer cells, although the reasons for this are still not fully understood. As a result, cancer is much more common in people over 60. The immune system must have the ability to both identify and destroy problem cells, and if either of these roles is compromised, the result can be full blown disease.

    But science is now learning how to leverage the many remarkable abilities of the human immune system, tweaking it in such a way as to help it identify and then take successful action against cancerous and other corrupted cells. Immunotherapy is just now beginning to appear on the public stage with treatments that partner with the body instead of fighting it.

    Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. The company's immunotherapies are based on a novel platform technology involving the use of live, attenuated bacteria that are bio-engineered to secrete antigen/adjuvant fusion protein(s) that redirect the powerful immune response all human beings have to the bacterium to the cancer itself. In effect, the approach puts cancer in the line of fire.

    ADXS-HPV, the company's main anti-cancer drug, is currently being evaluated in 5 clinical trials for HPV-associated diseases, including cervical cancer, head and neck cancer, and anal cancer, and the company has over 15 distinct constructs in various stages of development.

    For additional information, visit Advaxis.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: ADXS
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.